BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol 2017;53:128-49. [PMID: 28274597 DOI: 10.1016/j.arbres.2017.02.001] [Cited by in Crossref: 194] [Cited by in F6Publishing: 227] [Article Influence: 38.8] [Reference Citation Analysis]
Number Citing Articles
1 Su KC, Ko HK, Hsiao YH, Chou KT, Chen YW, Yu WK, Pan SW, Feng JY, Perng DW. Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial. Arch Bronconeumol 2022;58:601-10. [PMID: 35312525 DOI: 10.1016/j.arbres.2021.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Arellano-orden E, Calero Acuña C, Sánchez-lópez V, López Ramírez C, Otero-candelera R, Marín-hinojosa C, López Campos J. Cellular mechanisms involved in the pathogenesis of airway remodeling in chronic lung disease. European Clinical Respiratory Journal 2022;9:2097377. [DOI: 10.1080/20018525.2022.2097377] [Reference Citation Analysis]
3 Joean O, Welte T. Vaccination and modern management of chronic obstructive pulmonary disease - a narrative review. Expert Rev Respir Med 2022;:1-10. [PMID: 35713962 DOI: 10.1080/17476348.2022.2092099] [Reference Citation Analysis]
4 Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond) 2022;136:405-23. [PMID: 35319068 DOI: 10.1042/CS20210835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xiao T, Wijnant SRA, van der Velpen I, Terzikhan N, Lahousse L, Ikram MK, Vernooij MW, Brusselle GG, Ikram MA. Lung function impairment in relation to cognition and vascular brain lesions: the Rotterdam Study. J Neurol 2022. [PMID: 35267082 DOI: 10.1007/s00415-022-11027-9] [Reference Citation Analysis]
6 Baos S, Cremades-jimeno L, López-ramos M, de Pedro MÁ, Uriarte SA, Sastre J, González-mangado N, Rodríguez-nieto MJ, Peces-barba G, Cárdaba B. Expression of Macrophage Scavenger Receptor (MSR1) in Peripheral Blood Cells from Patients with Different Respiratory Diseases: Beyond Monocytes. JCM 2022;11:1439. [DOI: 10.3390/jcm11051439] [Reference Citation Analysis]
7 Zuo X, Lou P, Zhu Y, Chen B, Zhu X, Chen P, Dong Z, Zhu X, Li T, Zhang P. Effects of expressive art therapy on health status of patients with chronic obstructive pulmonary disease: a community-based cluster randomized controlled trial. Ther Adv Respir Dis 2022;16:17534666221111876. [PMID: 35850588 DOI: 10.1177/17534666221111876] [Reference Citation Analysis]
8 Alcázar-Navarrete B, Díaz-Lopez JM, García-Flores P, Ortega-Antelo M, Aguilar-Cruz I, Ruiz-Rodríguez O, Santiago-Diaz P, Romero Palacios PJ. T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2021:S0300-2896(21)00386-0. [PMID: 35312535 DOI: 10.1016/j.arbres.2021.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lin S, Ma Z, Huang Y, Sun Y, Yi H. Chronic obstructive pulmonary disease is characterized by reduced levels and defective suppressive function of regulatory B cells in peripheral blood. Mol Immunol 2021;141:87-93. [PMID: 34837778 DOI: 10.1016/j.molimm.2021.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 García García MDC, Hernández Borge J, García García GM, Márquez Pérez FL. Supervivencia en pacientes con EPOC en tratamiento con oxigenoterapia continua domiciliaria. Open Respiratory Archives 2021;3:100119. [DOI: 10.1016/j.opresp.2021.100119] [Reference Citation Analysis]
11 Lu J, Xie L, Sun S. The inhibitor miR-21 regulates macrophage polarization in an experimental model of chronic obstructive pulmonary disease. Tob Induc Dis 2021;19:69. [PMID: 34539308 DOI: 10.18332/tid/140095] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Marín-Hinojosa C, Eraso CC, Sanchez-Lopez V, Hernández LC, Otero-Candelera R, Lopez-Campos JL. Nutriepigenomics and chronic obstructive pulmonary disease: potential role of dietary and epigenetics factors in disease development and management. Am J Clin Nutr 2021:nqab267. [PMID: 34477827 DOI: 10.1093/ajcn/nqab267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Andelius DK, Hilberg O, Ibsen R, Løkke A. National Epidemiological Case-Control Study of Pharmacological Smoking Cessation Treatment in Danish Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2021;16:2433-43. [PMID: 34465989 DOI: 10.2147/COPD.S317118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Carrasco Hernández L, Caballero Eraso C, Abad Arranz M, Márquez Martín E, Calero Acuña C, Lopez-campos JL. Time-based Register and Analysis of COPD Endpoints (TRACE) Project: Methodology and Workflow. Archivos de Bronconeumología 2021;57:593-4. [DOI: 10.1016/j.arbres.2020.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kotlyarov S, Kotlyarova A. Bioinformatic Analysis of ABCA1 Gene Expression in Smoking and Chronic Obstructive Pulmonary Disease. Membranes (Basel) 2021;11:674. [PMID: 34564491 DOI: 10.3390/membranes11090674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wang Y. Effects of Doxofylline Combined with Ceftazidime on Clinical Efficacy, Drug Safety, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease Complicated with Infection. Med Sci Monit 2021;27:e930494. [PMID: 34404757 DOI: 10.12659/MSM.930494] [Reference Citation Analysis]
17 Schwarz SB, Mathes T, Majorski DS, Wollsching-Strobel M, Kroppen D, Magnet FS, Windisch W. Living conditions and autonomy levels in COPD patients receiving non-invasive ventilation: impact on health related quality of life. BMC Pulm Med 2021;21:255. [PMID: 34344338 DOI: 10.1186/s12890-021-01621-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Spielmanns M, Tamm M, Schildge S, Valipour A. Swiss Experience in Therapy With Dual Bronchodilation in Chronic Obstructive Pulmonary Disease in Relation to Self-Reported Physical Functionality. J Clin Med Res 2021;13:392-402. [PMID: 34394782 DOI: 10.14740/jocmr4542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Granell-Gil M, Murcia-Anaya M, Sevilla S, Martínez-Plumed R, Biosca-Pérez E, Cózar-Bernal F, Garutti I, Gallart L, Ubierna-Ferreras B, Sukia-Zilbeti I, Gálvez-Muñoz C, Delgado-Roel M, Mínguez L, Bermejo S, Valencia O, Real M, Unzueta C, Ferrando C, Sánchez F, González S, Ruiz-Villén C, Lluch A, Hernández A, Hernández-Beslmeisl J, Vives M, Vicente R. Clinical guide to perioperative management for videothoracoscopy lung resection (Section of Cardiac, Vascular and Thoracic Anesthesia, SEDAR; Spanish Society of Thoracic Surgery, SECT; Spanish Society of Physiotherapy). Rev Esp Anestesiol Reanim 2021:S0034-9356(21)00129-8. [PMID: 34330548 DOI: 10.1016/j.redar.2021.03.005] [Reference Citation Analysis]
20 Yi E, Zhang J, Zheng M, Zhang Y, Liang C, Hao B, Hong W, Lin B, Pu J, Lin Z, Huang P, Li B, Zhou Y, Ran P. Long noncoding RNA IL6-AS1 is highly expressed in chronic obstructive pulmonary disease and is associated with interleukin 6 by targeting miR-149-5p and early B-cell factor 1. Clin Transl Med 2021;11:e479. [PMID: 34323408 DOI: 10.1002/ctm2.479] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Tang M, Long Y, Liu S, Yue X, Shi T. Prevalence of Cardiovascular Events and Their Risk Factors in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Overlap Syndrome. Front Cardiovasc Med 2021;8:694806. [PMID: 34336955 DOI: 10.3389/fcvm.2021.694806] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Zhao Y, Li M, Yang Y, Wu T, Huang Q, Wu Q, Ren C. Identification of Macrophage Polarization-Related Genes as Biomarkers of Chronic Obstructive Pulmonary Disease Based on Bioinformatics Analyses. Biomed Res Int 2021;2021:9921012. [PMID: 34250093 DOI: 10.1155/2021/9921012] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Conen K, Guthrie DM, Stevens T, Winemaker S, Seow H. Symptom trajectories of non-cancer patients in the last six months of life: Identifying needs in a population-based home care cohort. PLoS One 2021;16:e0252814. [PMID: 34129643 DOI: 10.1371/journal.pone.0252814] [Reference Citation Analysis]
24 Lei Y, Zou K, Xin J, Wang Z, Liang K, Zhao L, Ma X. Sedentary behavior is associated with chronic obstructive pulmonary disease: A generalized propensity score-weighted analysis. Medicine (Baltimore) 2021;100:e25336. [PMID: 33950922 DOI: 10.1097/MD.0000000000025336] [Reference Citation Analysis]
25 Song L, Peng J, Guo X. Exosomal lncRNA TCONS_00064356 derived from injured alveolar epithelial type II cells affects the biological characteristics of mesenchymal stem cells. Life Sci 2021;278:119568. [PMID: 33964296 DOI: 10.1016/j.lfs.2021.119568] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Patel AA, Ryan GW, Tisnado D, Chuang E, Walling AM, Saab S, Khemichian S, Sundaram V, Brook RH, Wenger NS. Deficits in Advance Care Planning for Patients With Decompensated Cirrhosis at Liver Transplant Centers. JAMA Intern Med 2021;181:652-60. [PMID: 33720273 DOI: 10.1001/jamainternmed.2021.0152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 de-Torres JP, O'Donnell DE, Marín JM, Cabrera C, Casanova C, Marín M, Ezponda A, Cosio BG, Martinez C, Solanes I, Fuster A, Neder JA, Gonzalez-Gutierrez J, Celli BR. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest 2021;160:872-8. [PMID: 33901498 DOI: 10.1016/j.chest.2021.04.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dietl B, Henares D, Boix-Palop L, Muñoz-Almagro C, Garau J, Calbo E. Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome. Front Med (Lausanne) 2021;8:650271. [PMID: 33996857 DOI: 10.3389/fmed.2021.650271] [Reference Citation Analysis]
29 Kotlyarov S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int J Mol Sci 2021;22:3334. [PMID: 33805156 DOI: 10.3390/ijms22073334] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
30 Spruit MA, Van't Hul A, Vreeken HL, Beekman E, Post MHT, Meerhoff GA, Van der Valk AL, Zagers C, Sillen MJH, Vooijs M, Custers J, Muris J, Langer D, Donkers J, Bregman M, Tissink L, Bergkamp E, Wempe J, Houben-Wilke S, Augustin IML, Bij de Vaate E, Franssen FFM, Van Ranst D, Van der Vaart H, Antons J, Van Doormaal M, Koolen EH, Van der Wees P, Van Snippenburg R, Janssen DJA, Simons S. Profiling of Patients with COPD for Adequate Referral to Exercise-Based Care: The Dutch Model. Sports Med 2020;50:1421-9. [PMID: 32333261 DOI: 10.1007/s40279-020-01286-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
31 Cosío BG, Shafiek H, Verdú J, Fiorentino F, Valera JL, Martínez R, Romero S, Ramón L, Toledo-Pons N, Sala E. Implementation of an Integrated Care Model for Frequent-Exacerbator COPD Patients: A Controlled Prospective Study. Arch Bronconeumol (Engl Ed) 2021:S0300-2896(21)00050-8. [PMID: 33771388 DOI: 10.1016/j.arbres.2021.01.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yang SH, Yang MC, Wu YK, Wu CW, Hsieh PC, Kuo CY, Tzeng IS, Lan CC. Poor Work Efficiency is Associated with Poor Exercise Capacity and Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2021;16:245-56. [PMID: 33603352 DOI: 10.2147/COPD.S283005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Yuan D, Liu Y, Li M, Zhou H, Cao L, Zhang X, Li Y. Senescence associated long non-coding RNA 1 regulates cigarette smoke-induced senescence of type II alveolar epithelial cells through sirtuin-1 signaling. J Int Med Res 2021;49:300060520986049. [PMID: 33535826 DOI: 10.1177/0300060520986049] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Calle Rubio M, Rodriguez Hermosa JL, de Torres JP, Marín JM, Martínez-González C, Fuster A, Cosío BG, Peces-Barba G, Solanes I, Feu-Collado N, Lopez-Campos JL, Casanova C; CHAIN Study Investigators. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respir Res 2021;22:36. [PMID: 33541356 DOI: 10.1186/s12931-021-01633-y] [Reference Citation Analysis]
35 López-Campos JL, Calle Rubio M, Izquierdo Alonso JL, Fernández-Villar A, Abascal-Bolado B, Alcázar B, García-Río F, Peces-Barba G, Serra Batlles J, Martínez Garcerán JJ, Riesco Miranda JA, Figueira-Gonçalves JM, Soler-Cataluña JJ, Temprano M, Ortega Ruiz F, Santos Pérez S, Álvarez Martínez CJ. Forum COPD Working Group Consensus on the Diagnosis, Treatment and Follow-Up of COPD. Arch Bronconeumol (Engl Ed) 2021:S0300-2896(21)00023-5. [PMID: 33674118 DOI: 10.1016/j.arbres.2020.12.037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Zhang Q, Wang T, Jin J, Shi X, Huang A, Ma Z, Li J, Wang S, Z Ma R, Fang Q. Rcn3 Suppression Was Responsible for Partial Relief of Emphysema as Shown by Specific Type II Alveolar Epithelial Cell Rcn3 CKO Mouse Model. Int J Chron Obstruct Pulmon Dis 2021;16:147-58. [PMID: 33531801 DOI: 10.2147/COPD.S272711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Soler-Cataluña JJ, Almagro P, Huerta A, González-Segura D, Cosío BG; CLAVE study Investigators. Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study. Int J Chron Obstruct Pulmon Dis 2021;16:137-46. [PMID: 33531800 DOI: 10.2147/COPD.S285385] [Reference Citation Analysis]
38 Zozina VI, Covantev S, Kukes VG, Corlateanu A. Coenzyme Q10 in COPD: An Unexplored Opportunity? COPD 2021;18:114-22. [PMID: 33441012 DOI: 10.1080/15412555.2020.1849084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Rodríguez Hermosa JL, Fuster Gomila A, Puente Maestu L, Amado Diago CA, Callejas González FJ, Malo De Molina Ruiz R, Fuentes Ferrer ME, Alvarez-Sala JL, Calle Rubio M. Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD. Int J Chron Obstruct Pulmon Dis 2021;16:53-65. [PMID: 33447026 DOI: 10.2147/COPD.S279394] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-cataluña JJ, García-río F, Casanova C, Rodríguez González-moro JM, Cosío BG, Sánchez G, Ancochea J. Prevalence and Determinants of COPD in Spain: EPISCAN II. Archivos de Bronconeumología (English Edition) 2021;57:61-9. [DOI: 10.1016/j.arbr.2020.07.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
41 Estrada-Alvarez JM, Orozco-Hernández JP, Aristizabal-Franco LE. Validation of chronic obstructive pulmonary disease severity score (COPDSS) for primary care in a Colombian population. Biomedica 2020;40:664-72. [PMID: 33275345 DOI: 10.7705/biomedica.5123] [Reference Citation Analysis]
42 Tang J, Curull V, Wang X, Ampurdanés C, Duran X, Pijuan L, Rodríguez-Fuster A, Aguiló R, Yélamos J, Barreiro E. Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD. Cancers (Basel) 2020;12:E3333. [PMID: 33187221 DOI: 10.3390/cancers12113333] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Alcazar-Navarrete B, Fuster A, García Sidro P, García Rivero JL, Abascal-Bolado B, Pallarés-Sanmartín A, Márquez E, Valido-Morales A, Boldova Loscertales A, Callejas-Gonzalez FJ, Palop M, Riesco JA, Golpe R, Soler-Cataluña JJ, Miravitlles M. Relationship Between Clinical Control, Respiratory Symptoms and Quality of Life for Patients with COPD. Int J Chron Obstruct Pulmon Dis 2020;15:2683-93. [PMID: 33149566 DOI: 10.2147/COPD.S265470] [Reference Citation Analysis]
44 Kachroo P, Morrow JD, Kho AT, Vyhlidal CA, Silverman EK, Weiss ST, Tantisira KG, Demeo DL. Co-methylation analysis in lung tissue identifies pathways for fetal origins of COPD. Eur Respir J 2020;56:1902347. [DOI: 10.1183/13993003.02347-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
45 Wang C, Zhou J, Wang J, Li S, Fukunaga A, Yodoi J, Tian H. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther 2020;5:248. [PMID: 33110061 DOI: 10.1038/s41392-020-00345-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
46 Greiner B, Ottwell R, Corcoran A, Hartwell M. Smoking and Physical Activity Patterns of U.S. Military Veterans With Chronic Obstructive Pulmonary Disease: An Analysis of 2017 Behavioral Risk Factor Surveillance System. Mil Med 2020:usaa330. [PMID: 33007087 DOI: 10.1093/milmed/usaa330] [Reference Citation Analysis]
47 Tang J, Ramis-Cabrer D, Curull V, Mateu-Jiménez M, Almagro K, Duran X, Pijuan L, Rodríguez-Fuster A, Aguiló R, Barreiro E. Markers of Stroma in Lung Cancer: Influence of COPD. Arch Bronconeumol (Engl Ed) 2021;57:130-7. [PMID: 33077297 DOI: 10.1016/j.arbres.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-Cataluña JJ, García-Río F, Casanova C, Rodríguez González-Moro JM, Cosío BG, Sánchez G, Ancochea J. Prevalence and Determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol (Engl Ed) 2021;57:61-9. [PMID: 32950310 DOI: 10.1016/j.arbres.2020.07.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
49 Tang J, Ramis-Cabrer D, Curull V, Wang X, Mateu-Jiménez M, Pijuan L, Duran X, Qin L, Rodríguez-Fuster A, Aguiló R, Barreiro E. B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors. Cancers (Basel) 2020;12:E2644. [PMID: 32947928 DOI: 10.3390/cancers12092644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
50 Zhuang H, Li N, Chen S, Shen Y, Zhan W, Xu X, Zhuo S. Correlation between level of autophagy and frequency of CD8+ T cells in patients with chronic obstructive pulmonary disease. J Int Med Res 2020;48:300060520952638. [PMID: 32910701 DOI: 10.1177/0300060520952638] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Krebs-Demmer L, Ronit A, Sigvardsen PE, Lebech AM, Gerstoft J, Knudsen AD, Fuchs A, Kühl JT, Nordestgaard BG, Kofoed KF, Nielsen SD. Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls. HIV Med 2020;21:625-34. [PMID: 32902086 DOI: 10.1111/hiv.12916] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
52 Savran O, Godtfredsen N, Sørensen T, Jensen C, Ulrik CS. COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines? Chron Respir Dis 2019;16:1479973119867949. [PMID: 31431060 DOI: 10.1177/1479973119867949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
53 Freire APCF, Ferreira AD, Santos CP, Araújo ICD, Uzeloto JS, Silva BSA, Ramos D, Ramos EMC. Body image in COPD and its relation with physical activity levels, lung function and body composition: An observational study. Clin Respir J 2020;14:1182-90. [PMID: 32790933 DOI: 10.1111/crj.13259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Alcázar-Navarrete B, Echave-Sustaeta JM. Microspirometers in the Follow-Up of COPD: Advantages and Disadvantages. Arch Bronconeumol (Engl Ed) 2021;57:160-1. [PMID: 32798006 DOI: 10.1016/j.arbres.2020.06.026] [Reference Citation Analysis]
55 Riesco JA, Hidalgo M, Chipayo D, Gómez JJ, Zaragozá F. Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit. Adv Ther 2020;37:3562-70. [PMID: 32588373 DOI: 10.1007/s12325-020-01403-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 da Silva CO, Gicquel T, Daniel Y, Bártholo T, Vène E, Loyer P, Pôrto LC, Lagente V, Victoni T. Alteration of immunophenotype of human macrophages and monocytes after exposure to cigarette smoke. Sci Rep 2020;10:12796. [PMID: 32732964 DOI: 10.1038/s41598-020-68753-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
57 Nakamaru Y, Suzuki M, Honma A, Nakazono A, Kimura S, Fujiwara K, Morita S, Konno S, Homma A. Preoperative Pulmonary Function Testing to Predict Recurrence of Chronic Rhinosinusitis With Nasal Polyps. Allergy Rhinol (Providence) 2020;11:2152656720946994. [PMID: 32844045 DOI: 10.1177/2152656720946994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Anzueto A, Miravitlles M. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development. Respir Res 2020;21:199. [PMID: 32727455 DOI: 10.1186/s12931-020-01407-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Huang Q, Xiong H, Shuai T, Wang Y, Zhang C, Zhang M, Zhu L, Lu J, Liu J. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2020;14:1753466620938546. [PMID: 32643535 DOI: 10.1177/1753466620938546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Miravitlles M, Marín A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD. Int J Chron Obstruct Pulmon Dis 2020;15:1643-54. [PMID: 32764910 DOI: 10.2147/COPD.S253567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
61 Lopez-Campos JL, Carrasco-Hernandez L, Quintana-Gallego E, Calero-Acuña C, Márquez-Martín E, Ortega-Ruiz F, Soriano JB. Triple therapy for COPD: a crude analysis from a systematic review of the evidence. Ther Adv Respir Dis 2019;13:1753466619885522. [PMID: 31694491 DOI: 10.1177/1753466619885522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Chai L, Feng W, Zhai C, Shi W, Wang J, Yan X, Wang Q, Zhang Q, Li M. The association between cystatin C and COPD: a meta-analysis and systematic review. BMC Pulm Med 2020;20:182. [PMID: 32586317 DOI: 10.1186/s12890-020-01208-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Pirina P, Zinellu E, Martinetti M, Spada C, Piras B, Collu C, Fois AG; COPD-HF Study Group. Treatment of COPD and COPD-heart failure comorbidity in primary care in different stages of the disease. Prim Health Care Res Dev 2020;21:e16. [PMID: 32498750 DOI: 10.1017/S1463423620000079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tang J, Ramis-Cabrer D, Curull V, Wang X, Qin L, Mateu-Jiménez M, Duran X, Pijuan L, Rodríguez-Fuster A, Espases RA, Barreiro E. Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD. Cancers (Basel) 2020;12:E1217. [PMID: 32414037 DOI: 10.3390/cancers12051217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
65 de-Torres JP, Wisnivesky JP, Bastarrika G, Wilson DO, Celli BR, Zulueta JJ. Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Arch Bronconeumol (Engl Ed) 2021;57:36-41. [PMID: 32409195 DOI: 10.1016/j.arbres.2020.03.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
66 Wizenty J, Schumann T, Theil D, Stockmann M, Pratschke J, Tacke F, Aigner F, Wuensch T. Recent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic Tissues. Molecules 2020;25:E2095. [PMID: 32365790 DOI: 10.3390/molecules25092095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Gaeckle NT, Stephenson L, Reilkoff RA. Alpha-1 Antitrypsin Deficiency and Pregnancy. COPD 2020;17:326-32. [PMID: 32308050 DOI: 10.1080/15412555.2020.1754778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lin M, Li X, Wang J, Cheng C, Zhang T, Han X, Song Y, Wang Z, Wang S. Saliva Microbiome Changes in Patients With Periodontitis With and Without Chronic Obstructive Pulmonary Disease. Front Cell Infect Microbiol 2020;10:124. [PMID: 32351901 DOI: 10.3389/fcimb.2020.00124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
69 Criner GJ, Delage A, Voelker K, Hogarth DK, Majid A, Zgoda M, Lazarus DR, Casal R, Benzaquen SB, Holladay RC, Wellikoff A, Calero K, Rumbak MJ, Branca PR, Abu-Hijleh M, Mallea JM, Kalhan R, Sachdeva A, Kinsey CM, Lamb CR, Reed MF, Abouzgheib WB, Kaplan PV, Marrujo GX, Johnstone DW, Gasparri MG, Meade AA, Hergott CA, Reddy C, Mularski RA, Case AH, Makani SS, Shepherd RW, Chen B, Holt GE, Martel S. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am J Respir Crit Care Med 2019;200:1354-62. [PMID: 31365298 DOI: 10.1164/rccm.201902-0383OC] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 20.0] [Reference Citation Analysis]
70 Kong ZB, Wang XD, Shen SR, Liu H, Zhou L, Chen B, Chen Z, Yin SJ. Risk Prediction for Arrhythmias by Heart Rate Deceleration Runs in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:585-93. [PMID: 32231431 DOI: 10.2147/COPD.S234470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Weber J, Reeves AP, Doucette JT, Jeon Y, Sood A, San José Estépar R, Celedón JC, de la Hoz RE. Quantitative CT Evidence of Airway Inflammation in WTC Workers and Volunteers with Low FVC Spirometric Pattern. Lung 2020;198:555-63. [PMID: 32239319 DOI: 10.1007/s00408-020-00350-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
72 Torres-Duque CA, Casas A, Zabert G, Jardim JR, Celli B, Rodríguez-Roisin R. The Latin American Thoracic Association (ALAT): 30 Years of History. Arch Bronconeumol (Engl Ed) 2020;56:413-5. [PMID: 32245542 DOI: 10.1016/j.arbres.2020.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Fischer AM, Varga-szemes A, Martin SS, Sperl JI, Sahbaee P, Neumann D, Gawlitza J, Henzler T, Johnson CM, Nance JW, Schoenberg SO, Schoepf UJ. Artificial Intelligence-based Fully Automated Per Lobe Segmentation and Emphysema-quantification Based on Chest Computed Tomography Compared With Global Initiative for Chronic Obstructive Lung Disease Severity of Smokers. Journal of Thoracic Imaging 2020;35:S28-34. [DOI: 10.1097/rti.0000000000000500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
74 Xue T, Ma Z, Liu F, Du W, He L, Wang J, An C. Pneumocystis jirovecii colonization and its association with pulmonary diseases: a multicenter study based on a modified loop-mediated isothermal amplification assay. BMC Pulm Med 2020;20:70. [PMID: 32197601 DOI: 10.1186/s12890-020-1111-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
75 Choi J, Sim JK, Oh JY, Lee YS, Hur GY, Lee SY, Shim JJ, Moon JY, Min KH. Relationship between Particulate Matter (PM10) and Airway Inflammation Measured with Exhaled Nitric Oxide Test in Seoul, Korea. Can Respir J 2020;2020:1823405. [PMID: 32256904 DOI: 10.1155/2020/1823405] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Zhou J, Li Q, Liu C, Pang R, Yin Y. Plasma Metabolomics and Lipidomics Reveal Perturbed Metabolites in Different Disease Stages of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:553-65. [PMID: 32210549 DOI: 10.2147/COPD.S229505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
77 Brown LK, Miller A. Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC. Respir Med 2021;176:105921. [PMID: 33589144 DOI: 10.1016/j.rmed.2020.105921] [Reference Citation Analysis]
78 Liu Z, Chen S, Xu Y, Liu X, Xiong P, Fu Y. Surfactant protein A expression and distribution in human lung samples from smokers with or without chronic obstructive pulmonary disease in China. Medicine (Baltimore) 2020;99:e19118. [PMID: 32049827 DOI: 10.1097/MD.0000000000019118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lambert AA, Bhatt SP. Respiratory symptoms in smokers with normal spirometry: clinical significance and management considerations. Curr Opin Pulm Med 2019;25:138-43. [PMID: 30461536 DOI: 10.1097/MCP.0000000000000550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
80 Barrecheguren M, Kostikas K, Mezzi K, Shen S, Alcazar B, Soler-cataluña JJ, Miravitlles M, Wedzicha JA. COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. Thorax 2020;75:351-3. [DOI: 10.1136/thoraxjnl-2018-212752] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
81 Soler-cataluña JJ, Alcázar B, Miravitlles M. Clinical control in COPD: A New therapeutic objective? Archivos de Bronconeumología (English Edition) 2020;56:68-9. [DOI: 10.1016/j.arbr.2019.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
82 Fernández-garcía S, Represas-represas C, Ruano-raviña A, Mosteiro-añón M, Mouronte-roibas C, Fernández-villar A. Perfil social de los pacientes que ingresan por una agudización de EPOC. Un análisis desde una perspectiva de género. Archivos de Bronconeumología 2020;56:84-9. [DOI: 10.1016/j.arbres.2019.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
83 Soler-cataluña JJ, Alcázar B, Miravitlles M. Control clínico en la EPOC: ¿un nuevo objetivo terapéutico? Archivos de Bronconeumología 2020;56:68-9. [DOI: 10.1016/j.arbres.2019.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
84 Fernández-garcía S, Represas-represas C, Ruano-raviña A, Mosteiro-añón M, Mouronte-roibas C, Fernández-villar A. Social Profile of Patients Admitted for COPD Exacerbations. A Gender Analysis. Archivos de Bronconeumología (English Edition) 2020;56:84-9. [DOI: 10.1016/j.arbr.2019.03.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
85 Sahin H, Naz I, Susam S, Erbaycu AE, Olcay S. The effect of the presence and severity of bronchiectasis on the respiratory functions, exercise capacity, dyspnea perception, and quality of life in patients with chronic obstructive pulmonary disease. Ann Thorac Med 2020;15:26-32. [PMID: 32002044 DOI: 10.4103/atm.ATM_198_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
86 Bouza E, Alvar A, Almagro P, Alonso T, Ancochea J, Barbé F, Corbella J, Gracia D, Mascarós E, Melis J, Miravitlles M, Pastor M, Pérez P, Rudilla D, Torres A, Soriano JB, Vallano A, Vargas F, Palomo E. Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document. Rev Esp Quimioter 2020;33:49-67. [PMID: 31933347 DOI: 10.37201/req/2064.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
87 Li H, Zeng Z, Cheng J, Hu G, Li Y, Wei L, Zhou Y, Ran P. Prognostic Role of NT-proBNP for in-Hospital and 1-Year Mortality in Patients with Acute Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2020;15:57-67. [PMID: 32021144 DOI: 10.2147/COPD.S231808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
88 García-quero C, Carreras J, Martínez-cerón E, Casitas R, Galera R, Utrilla C, Torres I, García-río F. Small Airway Dysfunction Impairs Quality of Life Among Smokers With No Airflow Limitation. Archivos de Bronconeumología (English Edition) 2020;56:9-17. [DOI: 10.1016/j.arbr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernández ME, Saez MS; grupo de estudio DAAT.AR. Prevalence of Alpha-1 Antitrypsin Deficiency in COPD Patients in Argentina. The DAAT.AR Study. Arch Bronconeumol (Engl Ed) 2020;56:571-7. [PMID: 31889566 DOI: 10.1016/j.arbres.2019.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
90 Sun X, Shang J, Wu A, Xia J, Xu F. Identification of dynamic signatures associated with smoking-related squamous cell lung cancer and chronic obstructive pulmonary disease. J Cell Mol Med 2020;24:1614-25. [PMID: 31829519 DOI: 10.1111/jcmm.14852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
91 Butler SJ, Li LSK, Ellerton L, Gershon AS, Goldstein RS, Brooks D. Prevalence of comorbidities and impact on pulmonary rehabilitation outcomes. ERJ Open Res 2019;5:00264-2019. [PMID: 31832430 DOI: 10.1183/23120541.00264-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
92 Chaddha U, Lin J, Hogarth DK. Bronchoscopic Lung Volume Reduction Using Endobronchial Valves: How to Do It. Curr Pulmonol Rep 2019;8:189-97. [DOI: 10.1007/s13665-019-00236-9] [Reference Citation Analysis]
93 Rosas-Alonso R, Galera R, Sánchez-Pascuala JJ, Casitas R, Burdiel M, Martínez-Cerón E, Vera O, Rodriguez-Antolin C, Pernía O, De Castro J, García-Rio F, Ibanez-de-Cáceres I. Hypermethylation of Anti-oncogenic MicroRNA 7 is Increased in Emphysema Patients. Arch Bronconeumol (Engl Ed) 2020;56:506-13. [PMID: 31780284 DOI: 10.1016/j.arbres.2019.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
94 Soler-Cataluña JJ, Alcázar B, Marzo M, Pérez J, Miravitlles M. Evaluation of Changes in Control Status in COPD: An Opportunity for Early Intervention. Chest 2020;157:1138-46. [PMID: 31759964 DOI: 10.1016/j.chest.2019.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
95 Koopman M, Spruit MA, Franssen FME, Delbressine J, Wouters EFM, Mathew D, Vink A, Vanfleteren LEGW. Effects of Non-Invasive Ventilation Combined with Oxygen Supplementation on Exercise Performance in COPD Patients with Static Lung Hyperinflation and Exercise-Induced Oxygen Desaturation: A Single Blind, Randomized Cross-Over Trial. J Clin Med 2019;8:E2012. [PMID: 31752201 DOI: 10.3390/jcm8112012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
96 Wu TD, Ejike CO, Wise RA, McCormack MC, Brigham EP. Investigation of the Obesity Paradox in Chronic Obstructive Pulmonary Disease, According to Smoking Status, in the United States. Am J Epidemiol 2019;188:1977-83. [PMID: 31504124 DOI: 10.1093/aje/kwz185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
97 Olschewski H, Canepa M, Kovacs G. Pulmonary and cardiac drugs: clinically relevant interactions. Herz 2019;44:517-21. [PMID: 31297545 DOI: 10.1007/s00059-019-4834-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Han Y, Wu Z, Chen Y, Kan Y, Geng M, Xu N, Qian H, Wang HF, Niu M. Factors associated with appendicular skeletal muscle mass among male Chinese patients with stable chronic obstructive pulmonary disease: A hospital-based cross-sectional study. Medicine (Baltimore) 2019;98:e17361. [PMID: 31577733 DOI: 10.1097/MD.0000000000017361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Zuo H, Xie X, Peng J, Wang L, Zhu R. Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Anal Cell Pathol (Amst) 2019;2019:5189165. [PMID: 31737467 DOI: 10.1155/2019/5189165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
100 López-Campos JL, Rodríguez DA, Quintana-Gallego E, Martínez-Llorens J, Carrasco Hernández L, Barreiro E. Ten Research Questions for Improving COPD Care in the Next Decade. COPD 2019;16:311-20. [PMID: 31576763 DOI: 10.1080/15412555.2019.1668919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Hong H, Huang C, Chen C, Zhou R, Li J, Liu J, Liu X. Efficacy and safety of acupoint autohemotherapy in treating stable chronic obstructive pulmonary disease: Protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e17291. [PMID: 31568014 DOI: 10.1097/MD.0000000000017291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Gonzalez-Barcala FJ, San-Jose ME, Nieto-Fontarigo JJ, Calvo-Alvarez U, Carreira JM, Garcia-Sanz MT, Muñoz X, Perez-Lopez-Corona MP, Gómez-Conde MJ, Casas-Fernández A, Valdes-Cuadrado L, Mateo-Mosquera L, Salgado FJ. Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations. Int J Clin Pract 2019;:e13423. [PMID: 31573721 DOI: 10.1111/ijcp.13423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
103 Huang X, Li Y, Guo X, Zhu Z, Kong X, Yu F, Wang Q. Identification of differentially expressed genes and signaling pathways in chronic obstructive pulmonary disease via bioinformatic analysis. FEBS Open Bio 2019;9:1880-99. [PMID: 31419078 DOI: 10.1002/2211-5463.12719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
104 Matsunaga K, Oishi K, Miravitlles M, Anzueto A. Time To Revise COPD Treatment Algorithm. Int J Chron Obstruct Pulmon Dis 2019;14:2229-34. [PMID: 31631994 DOI: 10.2147/COPD.S219051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
105 Barrecheguren M, Miravitlles M. COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No. Chest 2018;154:749-51. [PMID: 30290926 DOI: 10.1016/j.chest.2018.06.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
106 Du Y, Zhang H, Xu Y, Ding Y, Chen X, Mei Z, Ding H, Jie Z. Association among genetic polymorphisms of GSTP1, HO-1, and SOD-3 and chronic obstructive pulmonary disease susceptibility. Int J Chron Obstruct Pulmon Dis 2019;14:2081-8. [PMID: 31564855 DOI: 10.2147/COPD.S213364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
107 Tang J, Ramis-Cabrer D, Wang X, Barreiro E. Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events. Cancers (Basel) 2019;11:E1301. [PMID: 31487876 DOI: 10.3390/cancers11091301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
108 Tavakoli H, Johnson KM, FitzGerald JM, Sin DD, Gershon AS, Kendzerska T, Sadatsafavi M. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. Int J Chron Obstruct Pulmon Dis 2019;14:2003-13. [PMID: 31564848 DOI: 10.2147/COPD.S210897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
109 Alcázar Navarrete B, Ancochea Bermúdez J, García-río F, Izquierdo Alonso JL, Miravitlles M, Rodríguez González-moro JM, Soler-cataluña JJ. Paciente exacerbador con enfermedad pulmonar obstructiva crónica: recomendaciones en procesos diagnósticos, terapéuticos y asistenciales. Archivos de Bronconeumología 2019;55:478-87. [DOI: 10.1016/j.arbres.2019.02.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
110 Alcázar Navarrete B, Ancochea Bermúdez J, García-río F, Izquierdo Alonso JL, Miravitlles M, Rodríguez González-moro JM, Soler-cataluña JJ. Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care. Archivos de Bronconeumología (English Edition) 2019;55:478-87. [DOI: 10.1016/j.arbr.2019.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
111 López-Campos JL, Quintana Gallego E, Carrasco Hernández L. Status of and strategies for improving adherence to COPD treatment. Int J Chron Obstruct Pulmon Dis 2019;14:1503-15. [PMID: 31371936 DOI: 10.2147/COPD.S170848] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
112 Tickoo M, Ruthazer R, Bardia A, Doron S, Andujar-Vazquez GM, Gardiner BJ, Snydman DR, Kurz SG. The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before- after study. BMC Pulm Med 2019;19:118. [PMID: 31262278 DOI: 10.1186/s12890-019-0872-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
113 Alcazar J, Losa-Reyna J, Rodriguez-Lopez C, Navarro-Cruz R, Alfaro-Acha A, Ara I, García-García FJ, Alegre LM, Guadalupe-Grau A. Effects of concurrent exercise training on muscle dysfunction and systemic oxidative stress in older people with COPD. Scand J Med Sci Sports 2019;29:1591-603. [PMID: 31169924 DOI: 10.1111/sms.13494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
114 Abad-Arranz M, Moran-Rodríguez A, Mascarós Balaguer E, Quintana Velasco C, Abad Polo L, Núñez Palomo S, Gonzálvez Rey J, Fernández Vargas AM, Hidalgo Requena A, Helguera Quevedo JM, García Pardo M, Lopez-Campos JL. Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit. Int J Chron Obstruct Pulmon Dis 2019;14:1187-94. [PMID: 31239656 DOI: 10.2147/COPD.S199322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
115 Barreiro E, Salazar-degracia A, Sancho-muñoz A, Aguiló R, Rodríguez-fuster A, Gea J. Endoplasmic reticulum stress and unfolded protein response in diaphragm muscle dysfunction of patients with stable chronic obstructive pulmonary disease. Journal of Applied Physiology 2019;126:1572-86. [DOI: 10.1152/japplphysiol.00670.2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
116 Huang J, Zeng T, Tian Y, Wu Y, Yu J, Pei Z, Tan L. Clinical significance of high-mobility group box-1 (HMGB1) in subjects with type 2 diabetes mellitus (T2DM) combined with chronic obstructive pulmonary disease (COPD). J Clin Lab Anal 2019;33:e22910. [PMID: 31129918 DOI: 10.1002/jcla.22910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
117 Tian Y, Zeng T, Tan L, Wu Y, Yu J, Huang J, Pei Z. Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization. J Clin Lab Anal 2019;33:e22908. [PMID: 31106488 DOI: 10.1002/jcla.22908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
118 Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis 2019;14:1045-51. [PMID: 31190789 DOI: 10.2147/COPD.S155306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
119 Gea J, Martínez-llorens J. Muscle Dysfunction in Chronic Obstructive Pulmonary Disease: Latest Developments. Archivos de Bronconeumología (English Edition) 2019;55:237-8. [DOI: 10.1016/j.arbr.2018.07.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Chazova IE, Lazareva NV, Oshchepkova EV. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment efficasy (according to the national register of arterial hypertension). Ter Arkh 2019;91:4-10. [PMID: 31094451 DOI: 10.26442/00403660.2019.03.000110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Miravitlles M, Koblizek V, Esquinas C, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, Tudoric N, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Valipour A. Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study. Respir Med 2019;150:141-8. [PMID: 30961941 DOI: 10.1016/j.rmed.2019.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
122 Sun J, Zhao G. Clinical effects of lentinan combined with budesonide inhalation in treating acute exacerbation of chronic obstructive pulmonary disease under mechanical ventilation. Exp Ther Med 2019;17:1503-8. [PMID: 30867684 DOI: 10.3892/etm.2019.7149] [Reference Citation Analysis]
123 Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: identification and optimal treatment. Ther Adv Respir Dis 2018;12:1753466618805662. [PMID: 30336736 DOI: 10.1177/1753466618805662] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
124 Qin J, Deng X, Wei A, Qin Y, Wu Y, Liao L, Lin F. Correlation between hypocalcemia and acute exacerbation of chronic obstructive pulmonary disease in the elderly. Postgrad Med 2019;131:319-23. [PMID: 30806122 DOI: 10.1080/00325481.2019.1585689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
125 Rodríguez-Mañero M, López-Pardo E, Cordero A, Ruano-Ravina A, Novo-Platas J, Pereira-Vázquez M, Martínez-Gómez Á, García-Seara J, Martínez-Sande JL, Peña-Gil C, Mazón P, García-Acuña JM, Valdés-Cuadrado L, González-Juanatey JR. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis 2019;14:371-80. [PMID: 30863038 DOI: 10.2147/COPD.S174443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
126 Gea J, Pascual S, Castro-acosta A, Hernández-carcereny C, Castelo R, Márquez-martín E, Montón C, Palou A, Faner R, Furlong LI, Seijo L, Sanz F, Torà M, Vilaplana C, Casadevall C, López-campos JL, Monsó E, Peces-barba G, Cosío BG, Agustí A, Admetlló M, Agustí A, Alvarez-martínez C, Barreiro E, Casadevall C, Casals F, Castelo R, Castro-acosta A, Córdova R, Cosío BG, Faner R, Furlong LI, García M, Gea J, González-garcía JG, Hernández-carcereny C, López-campos JL, Márquez E, Monsó E, Montón C, Ormaza MJ, Palou A, Pascual S, Peces-barba G, Puigdevall P, Sanz F, Seijó L, Torà M, Torralba Y, Vilaplana C. The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumología (English Edition) 2019;55:93-9. [DOI: 10.1016/j.arbr.2018.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
127 Gea J, Pascual S, Castro-acosta A, Hernández-carcereny C, Castelo R, Márquez-martín E, Montón C, Palou A, Faner R, Furlong LI, Seijo L, Sanz F, Torà M, Vilaplana C, Casadevall C, López-campos JL, Monsó E, Peces-barba G, Cosío BG, Agustí A, Admetlló M, Agustí A, Alvarez-martínez C, Barreiro E, Casadevall C, Casals F, Castelo R, Castro-acosta A, Córdova R, Cosío BG, Faner R, Furlong LI, García M, Gea J, González-garcía JG, Hernández-carcereny C, López-campos JL, Márquez E, Monsó E, Montón C, Ormaza MJ, Palou A, Pascual S, Peces-barba G, Puigdevall P, Sanz F, Seijó L, Torà M, Torralba Y, Vilaplana C. Proyecto de biomarcadores y perfiles clínicos personalizados en la enfermedad pulmonar obstructiva crónica (proyecto BIOMEPOC). Archivos de Bronconeumología 2019;55:93-9. [DOI: 10.1016/j.arbres.2018.07.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
128 Weerahandi H, Wisnivesky JP, O'Conor R, Wolf MS, Federman AD. The Relationship of Illness Beliefs with Hospital and Emergency Department Utilization in Chronic Obstructive Pulmonary Disease. J Gen Intern Med 2019;34:923-8. [PMID: 30847827 DOI: 10.1007/s11606-019-04833-x] [Reference Citation Analysis]
129 Martín-Ontiyuelo C, Rodó-Pin A, Sancho-Muñoz A, Martinez-Llorens JM, Admetlló M, Molina L, Gea J, Barreiro E, Chiaradía DAR. Is iron deficiency modulating physical activity in COPD? Int J Chron Obstruct Pulmon Dis 2019;14:211-4. [PMID: 30666101 DOI: 10.2147/COPD.S182700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
130 Liu H, Song M, Zhai ZH, Shi RJ, Zhou XL. Group singing improves depression and life quality in patients with stable COPD: a randomized community-based trial in China. Qual Life Res. 2019;28:725-735. [PMID: 30612266 DOI: 10.1007/s11136-018-2063-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
131 Miravitlles M. What We Talk about When We Talk about Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2019;199:2-4. [PMID: 30092146 DOI: 10.1164/rccm.201807-1299ED] [Reference Citation Analysis]
132 Barreiro E, Sancho-Muñoz A, Puig-Vilanova E, Salazar-Degracia A, Pascual-Guardia S, Casadevall C, Gea J. Differences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexia. J Appl Physiol (1985) 2019;126:403-12. [PMID: 30543501 DOI: 10.1152/japplphysiol.00611.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
133 Townsend J, Adams V, Galiatsatos P, Pearse D, Pantle H, Masterson M, Kisuule F, Jacob E, Kiruthi C, Ortiz P, Agbanlog A, Jurao R, Stern S, Nayak S, Melgar M, Sama J, Irwin J, Mazidi C, Psoter K, McKenzie R. Procalcitonin-Guided Antibiotic Therapy Reduces Antibiotic Use for Lower Respiratory Tract Infections in a United States Medical Center: Results of a Clinical Trial. Open Forum Infect Dis 2018;5:ofy327. [PMID: 30619913 DOI: 10.1093/ofid/ofy327] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
134 Jobst BJ, Owsijewitsch M, Kauczor HU, Biederer J, Ley S, Becker N, Kopp-Schneider A, Delorme S, Heussel CP, Puderbach M, Wielpütz MO, Ley-Zaporozhan J. GOLD stage predicts thoracic aortic calcifications in patients with COPD. Exp Ther Med 2019;17:967-73. [PMID: 30651888 DOI: 10.3892/etm.2018.7039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Soler-Cataluña JJ, Marzo M, Catalán P, Miralles C, Alcazar B, Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis 2018;13:3719-31. [PMID: 30532528 DOI: 10.2147/COPD.S178149] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
136 Jung JH, Lim YH, Lee JW, Choi WA, Suh MR, Kang SW. Remarkable improvement in a very severe chronic obstructive pulmonary disorder patient after use of noninvasive intermittent positive pressure ventilator: A case report. Medicine (Baltimore) 2018;97:e12877. [PMID: 30412081 DOI: 10.1097/MD.0000000000012877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Aggarwal S, Ahmad I, Lam A, Carlisle MA, Li C, Wells JM, Raju SV, Athar M, Rowe SM, Dransfield MT, Matalon S. Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema. JCI Insight 2018;3:120694. [PMID: 30385726 DOI: 10.1172/jci.insight.120694] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
138 Izquierdo JL, Miravitlles M, Esquinas C, Pérez M, Calle M, López Campos JL, Rodríguez González-moro JM, Casanova C, Esteban C, de Lucas P. Características de los pacientes con EPOC tratados en neumología en España según grupos GOLD y fenotipos clínicos GesEPOC. Archivos de Bronconeumología 2018;54:559-67. [DOI: 10.1016/j.arbres.2018.03.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
139 Soriano JB, García-Río F, Vázquez-Espinosa E, Conforto JI, Hernando-Sanz A, López-Yepes L, Galera-Martínez R, Peces-Barba G, Gotera-Rivera CM, Pérez-Warnisher MT, Segrelles-Calvo G, Zamarro C, González-Ponce P, Ramos MI, Jafri S, Ancochea J. A multicentre, randomized controlled trial of telehealth for the management of COPD. Respir Med 2018;144:74-81. [PMID: 30366588 DOI: 10.1016/j.rmed.2018.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
140 Gea J, Martínez-Llorens J. Muscle Dysfunction in Chronic Obstructive Pulmonary Disease: Latest Developments. Arch Bronconeumol (Engl Ed) 2019;55:237-8. [PMID: 30297244 DOI: 10.1016/j.arbres.2018.07.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
141 Hartman JE, Vanfleteren LEGW, van Rikxoort EM, Slebos DJ; on behalf of the SOLVE consortium. Bronchoscopic Lung Volume Reduction Treatment Using Endobronchial Valves for Emphysema: Emerging Questions. Respiration 2018;96:588-9. [PMID: 30286446 DOI: 10.1159/000491675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Barrecheguren M, Monteagudo M, Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim Care Respir Med 2018;28:36. [PMID: 30266978 DOI: 10.1038/s41533-018-0102-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
143 Park HJ, Byun MK, Rhee CK, Kim K, Kim HJ, Yoo KH. Significant predictors of medically diagnosed chronic obstructive pulmonary disease in patients with preserved ratio impaired spirometry: a 3-year cohort study. Respir Res 2018;19:185. [PMID: 30249256 DOI: 10.1186/s12931-018-0896-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
144 Yu D, Liu X, Zhang G, Ming Z, Wang T. Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF-κB Signaling Pathways. Front Pharmacol 2018;9:1001. [PMID: 30294270 DOI: 10.3389/fphar.2018.01001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
145 Sirois C, Lunghi C, Laroche ML, Maheux A, Frini A. The delicate choice of optimal basic therapy for multimorbid older adults: A cross-sectional survey. Res Social Adm Pharm 2019;15:761-6. [PMID: 30249377 DOI: 10.1016/j.sapharm.2018.09.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
146 Barrecheguren M, González C, Miravitlles M. What have we learned from observational studies and clinical trials of mild to moderate COPD? Respir Res 2018;19:177. [PMID: 30223834 DOI: 10.1186/s12931-018-0882-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
147 You B, Zhao Y, Hou S, Hu B, Li H. Lung volume reduction surgery in hypercapnic patients: a single-center experience from China. J Thorac Dis 2018;10:S2698-703. [PMID: 30210821 DOI: 10.21037/jtd.2018.05.195] [Reference Citation Analysis]
148 Li X, Zheng M, Pu J, Zhou Y, Hong W, Fu X, Peng Y, Zhou W, Pan H, Li B, Ran P. Identification of abnormally expressed lncRNAs induced by PM2.5 in human bronchial epithelial cells. Biosci Rep 2018;38:BSR20171577. [PMID: 29899163 DOI: 10.1042/BSR20171577] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
149 Guan C, Niu H. Frailty assessment in older adults with chronic obstructive respiratory diseases. Clin Interv Aging 2018;13:1513-24. [PMID: 30214171 DOI: 10.2147/CIA.S173239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
150 Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev 2018;27:180022. [PMID: 30068688 DOI: 10.1183/16000617.0022-2018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
151 Alcázar-navarrete B, Castellano Miñán F, Santiago Díaz P, Ruiz Rodríguez O, Romero Palacios PJ. Alveolar and Bronchial Nitric Oxide in Chronic Obstructive Pulmonary Disease and Asthma–COPD Overlap. Archivos de Bronconeumología (English Edition) 2018;54:414-9. [DOI: 10.1016/j.arbr.2018.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Martínez-gonzález C, Casanova C, de-Torres JP, Marín JM, de Lucas P, Fuster A, Cosío BG, Calle M, Peces-barba G, Solanes I, Agüero R, Feu-collado N, Alfageme I, Romero Plaza A, Balcells E, de Diego A, Marín Royo M, Moreno A, Llunell Casanovas A, Galdiz JB, Golpe R, Lacárcel Bautista C, Cabrera C, Marin A, Soriano JB, Lopez-campos JL. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. Chest 2018;154:274-85. [DOI: 10.1016/j.chest.2018.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
153 Jing X, Li Y, Xu J. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Can Respir J 2018;2018:7097540. [PMID: 30123392 DOI: 10.1155/2018/7097540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
154 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
155 Alfageme I, de Lucas P, Ancochea J, Miravitlles M, Soler-Cataluña JJ, García-Río F, Casanova C, Rodríguez González-Moro JM, Cosío BG, Sánchez G, Soriano JB. 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain -A Summary of the EPISCAN II Protocol. Arch Bronconeumol (Engl Ed) 2019;55:38-47. [PMID: 30612602 DOI: 10.1016/j.arbres.2018.05.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
156 Abad-Arranz M, Moran-Rodríguez A, Mascarós Balaguer E, Quintana Velasco C, Abad Polo L, Núñez Palomo S, Gonzálvez Rey J, Fernández Vargas AM, Hidalgo Requena A, Helguera Quevedo JM, García Pardo M, Lopez-Campos JL; COACH study investigators. Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care. BMC Med Res Methodol 2018;18:68. [PMID: 29970023 DOI: 10.1186/s12874-018-0528-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
157 Betancourt-peña J, Tonguino-rosero S, Rosero-carvajal H, Hurtado H. Diferencias de la rehabilitación pulmonar en pacientes con EPOC, con y sin indicación de oxígeno domiciliario a largo plazo. Fisioterapia 2018;40:169-77. [DOI: 10.1016/j.ft.2018.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
158 Krakowiak K, Durrington HJ. The Role of the Body Clock in Asthma and COPD: Implication for Treatment. Pulm Ther 2018;4:29-43. [PMID: 32026248 DOI: 10.1007/s41030-018-0058-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
159 Lopez-Campos JL, Carrasco Hernández L, Muñoz X, Bustamante V, Barreiro E. Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology 2018. [PMID: 29924458 DOI: 10.1111/resp.13341] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
160 Miravitlles M, Baek S, Vithlani V, Lad R. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same? Tuberc Respir Dis (Seoul) 2018;81:198-215. [PMID: 29926556 DOI: 10.4046/trd.2018.0040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
161 Joo H, Han D, Lee JH, Rhee CK. Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study. Tuberc Respir Dis (Seoul) 2018;81:299-304. [PMID: 29926552 DOI: 10.4046/trd.2018.0015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
162 Montes de Oca M, Laucho-Contreras ME. Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmornary Disease? What Do We Need to Add? Med Sci (Basel) 2018;6:E50. [PMID: 29904014 DOI: 10.3390/medsci6020050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
163 Kirby M, Coxson HO. Who Is at Risk? The Role of Airway Imaging in Chronic Lung Disease Risk Assessment. Annals ATS 2018;15:669-70. [DOI: 10.1513/annalsats.201804-244ed] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
164 Gayan-Ramirez G. Relevance of nutritional support and early rehabilitation in hospitalized patients with COPD. J Thorac Dis 2018;10:S1400-14. [PMID: 29928522 DOI: 10.21037/jtd.2018.03.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
165 Gea J, Sancho-Muñoz A, Chalela R. Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations. J Thorac Dis 2018;10:S1332-54. [PMID: 29928517 DOI: 10.21037/jtd.2018.02.66] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
166 Soler-cataluña JJ. Guías de práctica clínica o medicina personalizada en la enfermedad pulmonar obstructiva crónica. Archivos de Bronconeumología 2018;54:247-8. [DOI: 10.1016/j.arbres.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
167 Barreiro E, Jaitovich A. Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets. J Thorac Dis 2018;10:S1415-24. [PMID: 29928523 DOI: 10.21037/jtd.2018.04.168] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
168 Simoes DCM, Vogiatzis I. Can muscle protein metabolism be specifically targeted by exercise training in COPD? J Thorac Dis 2018;10:S1367-76. [PMID: 29928519 DOI: 10.21037/jtd.2018.02.67] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
169 Calle Rubio M, Rodríguez Hermosa JL, Soler-cataluña JJ, López-campos JL, Alcazar Navarrete B, Soriano JB, Rodríguez Gónzalez-moro JM, Fuentes Ferrer ME, Miravitlles M. Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL. Archivos de Bronconeumología 2018;54:270-9. [DOI: 10.1016/j.arbres.2017.11.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
170 Lakhdar R, Rabinovich RA. Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease? J Thorac Dis 2018;10:S1377-89. [PMID: 29928520 DOI: 10.21037/jtd.2018.05.81] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 de-Torres JP, Ezponda A, Alcaide AB, Campo A, Berto J, Gonzalez J, Zulueta JJ, Casanova C, Rodriguez-Delgado LE, Celli BR, Bastarrika G. Pulmonary arterial enlargement predicts long-term survival in COPD patients. PLoS One 2018;13:e0195640. [PMID: 29694376 DOI: 10.1371/journal.pone.0195640] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
172 Greising SM, Ottenheijm CAC, O'Halloran KD, Barreiro E. Diaphragm plasticity in aging and disease: therapies for muscle weakness go from strength to strength. J Appl Physiol (1985) 2018;125:243-53. [PMID: 29672230 DOI: 10.1152/japplphysiol.01059.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
173 Barreiro E, Puig-Vilanova E, Salazar-Degracia A, Pascual-Guardia S, Casadevall C, Gea J. The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia. J Appl Physiol (1985) 2018;125:287-303. [PMID: 29648516 DOI: 10.1152/japplphysiol.00798.2017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
174 Alcázar-Navarrete B, Castellano Miñán F, Santiago Díaz P, Ruiz Rodríguez O, Romero Palacios PJ. Alveolar and Bronchial Nitric Oxide in Chronic Obstructive Pulmonary Disease and Asthma-COPD Overlap. Arch Bronconeumol (Engl Ed) 2018;54:414-9. [PMID: 29627118 DOI: 10.1016/j.arbres.2018.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
175 Gea J. The Future of Biological Therapies in COPD. Archivos de Bronconeumología (English Edition) 2018;54:185-6. [DOI: 10.1016/j.arbr.2018.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
176 Fernández-Villar A, Represas-Represas C, Mouronte-Roibás C, Ramos-Hernández C, Priegue-Carrera A, Fernández-García S, López-Campos JL. Reliability and usefulness of spirometry performed during admission for COPD exacerbation. PLoS One 2018;13:e0194983. [PMID: 29579084 DOI: 10.1371/journal.pone.0194983] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
177 Hartman JE, Klooster K, Groen H, Ten Hacken NHT, Slebos DJ. Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care. Respirology 2018. [PMID: 29575395 DOI: 10.1111/resp.13295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
178 Marín-Oto M, Marín JM. Obstructive Sleep Apnea Syndrome and chronic obstructive pulmonary disease: Overlap or Syndrome. Arch Bronconeumol (Engl Ed) 2018;54:499-500. [PMID: 29576199 DOI: 10.1016/j.arbres.2018.02.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Lopez-Campos JL, Centanni S. Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management. COPD 2018;15:108-17. [PMID: 29558165 DOI: 10.1080/15412555.2018.1443064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
180 Wang L, Tang Y, Chen Y. HIF1A gene rs10873142 polymorphism is associated with risk of chronic obstructive pulmonary disease in a Chinese Han population: a case-control study. Biosci Rep 2018;38:BSR20171309. [PMID: 29339421 DOI: 10.1042/BSR20171309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
181 Vasileiadis IE, Goudis CA, Giannakopoulou PT, Liu T. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease? COPD 2018;15:148-56. [PMID: 29521545 DOI: 10.1080/15412555.2018.1432034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
182 Miravitlles M, Molina J, Quintano JA, Campuzano A, Pérez J, Roncero C; DEPREPOC study investigators. Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores. Int J Chron Obstruct Pulmon Dis 2018;13:823-31. [PMID: 29563782 DOI: 10.2147/COPD.S154791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
183 Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-rivero JL, Kemppinen A, Tee A, Roman-rodríguez M, Soler-cataluña JJ, Price DB. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respiratory Medicine 2018;136:8-14. [DOI: 10.1016/j.rmed.2018.01.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
184 Cho O, Oh YT, Chun M, Noh OK, Heo JS. Prognostic implication of FEV1/FVC ratio for limited-stage small cell lung cancer. J Thorac Dis. 2018;10:1797-1805. [PMID: 29707334 DOI: 10.21037/jtd.2018.02.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
185 Soriano JB. Brighter than GOLD. The Lancet Respiratory Medicine 2018;6:165-6. [DOI: 10.1016/s2213-2600(18)30001-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
186 Zhao S, Yang Q, Yu Z, Lv Y, Zhi J, Gustin P, Zhang W. Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats. PLoS One 2018;13:e0193610. [PMID: 29489916 DOI: 10.1371/journal.pone.0193610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
187 Hu HL, Nie ZQ, Lu Y, Yang X, Song C, Chen H, Zhu S, Chen BB, Huang J, Geng S, Zhao S. Circulating miR-125b but not miR-125a correlates with acute exacerbations of chronic obstructive pulmonary disease and the expressions of inflammatory cytokines. Medicine (Baltimore) 2017;96:e9059. [PMID: 29390434 DOI: 10.1097/MD.0000000000009059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
188 de Llano LP, Cosío BG, Iglesias A, de Las Cuevas N, Soler-Cataluña JJ, Izquierdo JL, López-Campos JL, Calero C, Plaza V, Miravitlles M, Torrego A, Martinez-Moragon E, Soriano JB, Viña AL, Bobolea I. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. Int J Chron Obstruct Pulmon Dis 2018;13:591-601. [PMID: 29483774 DOI: 10.2147/COPD.S153694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
189 Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators. Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J 2018;51:1702146. [PMID: 29437944 DOI: 10.1183/13993003.02146-2017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
190 Miravitlles M, Soler-cataluña JJ, Alcázar B, Viejo JL, García-río F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulmonary Pharmacology & Therapeutics 2018;48:97-103. [DOI: 10.1016/j.pupt.2017.10.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
191 Alcázar-navarrete B, Castellano Miñán F, Romero Palacios PJ. Futuro de la triple terapia en la enfermedad pulmonar obstructiva crónica. Archivos de Bronconeumología 2018;54:63-4. [DOI: 10.1016/j.arbres.2017.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
192 Kim DK, Lee J, Park JH, Yoo KH. What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure? Tuberc Respir Dis (Seoul) 2018;81:99-105. [PMID: 29372630 DOI: 10.4046/trd.2017.0094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
193 Mateu-Jimenez M, Curull V, Rodríguez-Fuster A, Aguiló R, Sánchez-Font A, Pijuan L, Gea J, Barreiro E. Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions. Clin Epigenetics 2018;10:7. [PMID: 29371906 DOI: 10.1186/s13148-017-0437-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
194 Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J Chron Obstruct Pulmon Dis 2018;13:183-7. [PMID: 29386887 DOI: 10.2147/COPD.S153770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
195 Nieto Cano S, Golpe Gómez R, Pérez de Llano LA. Necesidad de cuidados paliativos en pacientes respiratorios crónicos con patología no neoplásica. Archivos de Bronconeumología 2018;54:57. [DOI: 10.1016/j.arbres.2017.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Gea J. The Future of Biological Therapies in COPD. Arch Bronconeumol (Engl Ed) 2018;54:185-6. [PMID: 29291901 DOI: 10.1016/j.arbres.2017.11.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
197 Mohigefer J, Calero-Acuña C, Marquez-Martin E, Ortega-Ruiz F, Lopez-Campos JL. Understanding of COPD among final-year medical students. Int J Chron Obstruct Pulmon Dis 2018;13:131-9. [PMID: 29343952 DOI: 10.2147/COPD.S138539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
198 Tan HW, Xu YM, Wu DD, Lau ATY. Recent insights into human bronchial proteomics - how are we progressing and what is next? Expert Rev Proteomics 2018;15:113-30. [PMID: 29260600 DOI: 10.1080/14789450.2017.1417847] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
199 Echazarreta AL, Arias SJ, Del Olmo R, Giugno ER, Colodenco FD, Arce SC, Bossio JC, Armando G, Soriano JB; Grupo de estudio EPOC.AR. Prevalence of COPD in 6 Urban Clusters in Argentina: The EPOC.AR Study. Arch Bronconeumol (Engl Ed) 2018;54:260-9. [PMID: 29221827 DOI: 10.1016/j.arbres.2017.09.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
200 Carrión Valero F, Paulos Dos Santos S, Celli BR. Smoking In COPD Patients: A New Clinical Phenotype? Arch Bronconeumol (Engl Ed) 2018;54:249-50. [PMID: 29217210 DOI: 10.1016/j.arbres.2017.10.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
201 Luis López-Campos J, Fernández-Villar A, Represas Represas C, Marín Barrera L, Botana Rial M, López Ramírez C, Casamor R. Evaluation of clinical variables according to follow-up times in COPD: results from ON-SINT cohort. Eur Clin Respir J 2017;4:1394132. [PMID: 29201289 DOI: 10.1080/20018525.2017.1394132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Wei X, Shi Z, Cui Y, Mi J, Ma Z, Ren J, Li J, Xu S, Guo Y. Impulse oscillometry system as an alternative diagnostic method for chronic obstructive pulmonary disease. Medicine (Baltimore) 2017;96:e8543. [PMID: 29145259 DOI: 10.1097/MD.0000000000008543] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
203 Miravitlles M, Menezes A, López Varela MV, Casas A, Ugalde L, Ramirez-Venegas A, Mendoza L, López A, Wehrmeister FC, Surmont F, Montes de Oca M. Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study. Respir Med 2018;134:62-9. [PMID: 29413510 DOI: 10.1016/j.rmed.2017.11.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
204 Miravitlles M, Cosío BG, Arnedillo A, Calle M, Alcázar-Navarrete B, González C, Esteban C, Trigueros JA, Rodríguez González-Moro JM, Quintano Jiménez JA, Baloira A. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res 2017;18:198. [PMID: 29183382 DOI: 10.1186/s12931-017-0682-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
205 Hersh CP. Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine. F1000Res 2017;6:2049. [PMID: 29225784 DOI: 10.12688/f1000research.12399.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
206 Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res 2017;18:196. [PMID: 29178871 DOI: 10.1186/s12931-017-0683-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
207 Montes de Oca M, Menezes A, Wehrmeister FC, Lopez Varela MV, Casas A, Ugalde L, Ramirez-Venegas A, Mendoza L, López A, Surmont F, Miravitlles M. Adherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC study. PLoS One 2017;12:e0186777. [PMID: 29140978 DOI: 10.1371/journal.pone.0186777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
208 Calverley PMA, Magnussen H, Miravitlles M, Wedzicha JA. Triple Therapy in COPD: What We Know and What We Don't. COPD: Journal of Chronic Obstructive Pulmonary Disease 2017;14:648-62. [DOI: 10.1080/15412555.2017.1389875] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
209 Margo JA, Whiting MF, Brown CH, Hoover CK, Munir WM. The Effect of Chronic Pulmonary Disease and Mechanical Ventilation on Corneal Donor Endothelial Cell Density and Transplant Suitability. Am J Ophthalmol 2017;183:65-70. [PMID: 28890079 DOI: 10.1016/j.ajo.2017.08.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
210 Miravitlles M. Non-evidence based medicine: example of the use of systemic corticosteroids in exacerbation of COPD. Rev Clin Esp (Barc) 2017;217:520-1. [PMID: 29055656 DOI: 10.1016/j.rce.2017.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
211 de Torres JP, Marin JM, Martinez-gonzalez C, de Lucas-ramos P, Cosio B, Casanova C; for the COPD History Assessment In SpaiN (CHAIN) cohort. The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study: Longitudinal clinical cluster stability. Respirology 2018;23:485-91. [DOI: 10.1111/resp.13194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
212 Zagaceta J, Bastarrika G, Zulueta JJ, Colina I, Alcaide AB, Campo A, Divo M, Casanova C, Marin JM, Pinto-Plata VM, Celli BR, de-Torres JP. Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respir Res 2017;18:175. [PMID: 28962654 DOI: 10.1186/s12931-017-0658-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
213 Alcázar-Navarrete B, Castellano Miñán F, Romero Palacios PJ. Clinical Guidelines in Asthma and Chronic Obstructive Pulmonary Disease: How Useful Are They in Clinical Practice? Arch Bronconeumol (Engl Ed) 2018;54:117-8. [PMID: 28918869 DOI: 10.1016/j.arbres.2017.07.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
214 Baloira Villar A, Palop Cervera M. Does the Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease Really Exist? Arch Bronconeumol (Engl Ed) 2018;54:119-20. [PMID: 28918868 DOI: 10.1016/j.arbres.2017.07.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
215 Nibber A, Chisholm A, Soler-cataluña JJ, Alcazar B, Price D, Miravitlles M. Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom. COPD: Journal of Chronic Obstructive Pulmonary Disease 2017;14:504-12. [DOI: 10.1080/15412555.2017.1350154] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
216 Wootton SL, Mckeough Z, Ng CL, Jenkins S, Hill K, Eastwood PR, Hillman D, Jenkins C, Cecins N, Spencer L, Alison J. Effect on health-related quality of life of ongoing feedback during a 12-month maintenance walking programme in patients with COPD: a randomized controlled trial: Feedback during maintenance exercise. Respirology 2018;23:60-7. [DOI: 10.1111/resp.13128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
217 Harlander M, Barrecheguren M, Turel M, Miravitlles M. Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? COPD 2017;14:465-8. [PMID: 28745524 DOI: 10.1080/15412555.2017.1342233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
218 Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A; all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/). Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. Eur Respir J 2017;50:1700671. [PMID: 28679615 DOI: 10.1183/13993003.00671-2017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
219 Bird Y, Moraros J, Mahmood R, Esmaeelzadeh S, Kyaw Soe NM. Prevalence and associated factors of COPD among Aboriginal peoples in Canada: a cross-sectional study. Int J Chron Obstruct Pulmon Dis 2017;12:1915-22. [PMID: 28721036 DOI: 10.2147/COPD.S138304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
220 Miravitlles M, Anzueto A. Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics? Int J Mol Sci 2017;18:E1344. [PMID: 28644389 DOI: 10.3390/ijms18071344] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
221 Miravitlles M, Anzueto A, Jardim JR. Optimizing bronchodilation in the prevention of COPD exacerbations. Respir Res 2017;18:125. [PMID: 28633665 DOI: 10.1186/s12931-017-0601-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
222 Miravitlles M, Soler-cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumología (English Edition) 2017;53:324-35. [DOI: 10.1016/j.arbr.2017.03.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
223 Lopez-campos JL, Marquez-martín E, Ortega-ruiz F. Cambios mayores en la Guía española de la EPOC (GesEPOC) 2017: cruzando puentes. Archivos de Bronconeumología 2017;53:291-2. [DOI: 10.1016/j.arbres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
224 de-Torres JP, Marin JM. Differences between GesEPOC and GOLD in 2017. Arch Bronconeumol 2017;53:295-6. [PMID: 28506625 DOI: 10.1016/j.arbres.2017.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis 2017;12:1401-11. [PMID: 28546748 DOI: 10.2147/COPD.S132961] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
226 Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Antonio Riesco J, Simonet P, Rigau D, Soriano JB, Ancochea J. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol 2017;53:324-35. [PMID: 28477954 DOI: 10.1016/j.arbres.2017.03.018] [Cited by in Crossref: 237] [Cited by in F6Publishing: 250] [Article Influence: 47.4] [Reference Citation Analysis]